Verily gets a $Billion. With what data?
#JMP19 News: 2019 is already a fascinating year in digital health. New ways of collecting evidence in medicine are already big news ahead of #JPM19, the big JPMorgan conference life sciences and health tech conference in SF next week. Alphabet’s Verily getting a $1Billion investment led by Silver Lake Ventures.
Verily Projects are divided among sensors, interventions, platforms and precision medicine among the 17 listed on their website. Most have a Life Sciences partner. From the outside looking in at the projects Verily seems like little more like an outsourced dev shop for Pharma to experiment with digital therapeutics and patient tracking: Verily brings the technical talent to build the projects, the partners bring the clinical expertise.
Of course, to get $1Billion investment, you have to assume that there is much, much more to the story. According to the Christina Farr CNBC story on the investment, Verily was cash flow positive before this investment and they may be looking to make the company independent from Alphabet, the parent company of Google and Verily. Verily is part of Alphabet’s “other projects”. One can only imagine how much investors are expecting Verily to be worth if they are making a $Billion dollar investment. Certainly, they expect Verily has the potential to be $100 Billion Company or more. It’s all going to depend on the data, secondarily the algorithms and AI. Data is the prerequisite.
It would be fascinating to know just how much adoption Verily projects have and just how much data these projects can access. The core mission of Verily is to be better able to predict and prevent disease. To be able to predict and prevent disease, they’ll need a ton of data and a ton of analytics, of course. Presumably, they’ll need to mix it with other types of consumer data, the kind of data Google and Google investment companies will have access to.
Big Question: Where and how will they get all the data to make accurate predictions?